Chimerix, Inc.
Feb 28, 2017

Chimerix to Present at Cowen and Company 37th Annual Health Care Conference

DURHAM, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and   commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.                                                   

About Chimerix

Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant unmet medical needs.  Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com. 

CONTACT:

Investor Relations:

ir@chimerix.com

or

Will O'Connor

Stern Investor Relations

Will@sternir.com

212-362-1200



Media:

Becky Vonsiatsky

W2O Group

bvonsiatsky@w2ogroup.com

413-478-2003

Primary Logo

Source: Chimerix, Inc.

News Provided by Acquire Media